Prior to joining Maxion, Arndt has served as the Chief Scientific Officer of Affimed and held executive leadership roles as Executive Vice President of R&D at Kymab (acquired by Sanofi) and Chief Development Officer at MorphoSys as well as senior leadership roles at Genentech. During his 25-year career in the pharmaceutical industry, he established a successful track record of advancing therapeutics from research into early and late-stage clinical developments and in building valuable portfolios of drug candidates and pharma.

Prior to co-founding Maxion Therapeutics, John was a co-founder of Cambridge Antibody Technology (acquired by AstraZeneca) and IONTAS (acquired by FairJourney Biologics). John was an inventor of antibody phage display technology which earned the 2018 Nobel prize in chemistry (awarded to his co-inventor Sir Greg Winter). He also invented IONTAS’s proprietary Mammalian Display technology as well as Maxion’s KnotBody® technology.

Aneesh is the co-inventor of KnotBody® technology and co-founder of Maxion Therapeutics and IONTAS. Aneesh has over 10 years of experience in antibody and protein drug discovery against challenging targets at AstraZeneca, University of Cambridge and IONTAS.

Eva-Lotta brings significant Board Chair and Non-Executive Director (NED) experience from life science companies and 30 years of corporate, business development and operational expertise combined with a wealth of partnership experience from the biotech industry. As Immunocore’s Chief Business Officer (CBO), Eva-Lotta achieved USD $320 million Series A fundraising and established significant partnerships with top pharmaceutical companies over five years. Prior to that, she was CBO at Ablynx for seven years, participating in taking the company public and completed several strategic partnerships. Eva-Lotta is currently Chair of Draupnir Bio, and is NED at Almirall (where she also chairs the Nomination and Remuneration Committee), Aleta BioTherapeutics, and Crescendo Biologics.

Lucy is an investor in BGF’s early-stage team, with a focus on life sciences. Her main role is to source and execute new investments, as well as supporting a number of investee companies at board level. Prior to BGF, Lucy spent five years in strategy consulting at CIL where she focused on the healthcare and pharma sectors. Lucy holds a first-class degree in History from Durham University and a Master’s degree in Russian & Eastern European Studies from Oxford University.

Tim leads Monograph Capital’s investments in Maxion, Aviado, Ascend and Ouro Medicines. Prior to Monograph Capital, Tim was co-founder and VP Operations for MiroBio. Tim has been a biotech investor and company-builder at Syncona, Third Rock Ventures, and Oxford Sciences, gaining experience across therapeutic modalities and geographies. He began his career at the Boston Consulting Group in London. Tim trained as a pharmacologist, with an undergraduate degree from the University of Cambridge and DPhil from the University of Oxford.

Sohaib Mir is a Senior Investment Principal at LifeArc Ventures and has worked across investment banking, venture capital and clinical medicine. He was an Investment Director with ALSA Ventures, a Principal at Cambridge Innovation Capital and a member of Perella Weinberg Partners’ healthcare M&A team. Sohaib qualified in Medicine at the University of Birmingham where he also completed a PhD in CNS regeneration. He practiced medicine at Addenbrooke’s Hospital in Cambridge and gained an MPhil in Bioscience Enterprise from the University of Cambridge.

Elena Viboch is a Managing Director at General Catalyst, where she focuses on investing in life sciences. Her investments include ArriVent Biopharma, Cellanome, Dewpoint, Maze Therapeutics, Parabilis Medicines and Variant Bio, and she serves on the boards of ALLInBio, Faro Health, Paradigm and Pallando Therapeutics. Prior to joining General Catalyst, Elena served as an Investment Director at SoftBank, where she helped build SoftBank Vision Fund’s healthcare portfolio, driving investments in companies such as Devoted Health and Vividion Therapeutics and serving on multiple boards. Earlier in her career, Elena worked in investing at Kearny Venture Partners and held operating roles at Carmot Therapeutics and NanoString. She’s passionate about working closely with rising entrepreneurs to help them bring their work from idea to execution to impact. Elena holds a BA from Swarthmore College, an MS from Johns Hopkins University, and an MBA from Harvard Business School where she graduated with highest honors as a Baker Scholar. Elena lives in San Francisco and enjoys hiking throughout the Bay Area.

Emma is a Senior Investment Manager in the British Patient Capital Direct Investments team, where she focuses on breakthrough opportunities in the life sciences. Emma joined at the inception of the Direct Investment strategy and has led investments into companies spanning novel therapeutic modalities and technologies driving efficiencies in the life sciences sector. Previously, Emma spent three years investing in a broad array of life sciences companies for the Greater Manchester and Cheshire Life Sciences Fund managed by Catapult Ventures and has an academic background in Neuroscience.